CBDepot launches the sale of synthesized pharma-grade CBD
EU GMP CBD, pharm-grade synthesized CBD
CBDepot group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o.
During the CPHI 2017 event in Frankfurt, CBDepot introduced, as the first company in the EU, isolated GMP CBD via 3rd party contract manufacturer from Prague. Since summer 2019, the group took on a project of relocation of API Cannabidiol manufacture to new premises of CB21 Pharma in Brno.
“This allows CB21 Pharma to bring to the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot”, says Dr. Jan Storch, the CEO of CB21 Pharma.
The now launched synthesized pharma-grade CBD is compliant with the German DAC monograph.
“This addition will serve the GMP needs in applications or jurisdictions where the use of plant-based Cannabidiol API is not possible,” concludes Boris Baňas, group’s Chief Sales Officer.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance